IMM2902

DRUG2 trials

Sponsors

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Conditions

Advanced Breast CancerAdvanced CholangiocarcinomaAdvanced Gastric CancerAdvanced Gastric CarcinomaAdvanced Lung CancerAdvanced Solid Tumor

Phase 1

IMM2902, a HER2/SIRPα Bispecific MAb-Trap Antibody-receptor Fusion Protein, in Patients with HER2-expressing Advanced Solid Tumors

SuspendedNCT05076591

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.Advanced Breast Cancer, Advanced Gastric Cancer, Advanced Solid Tumor

Start: 2022-06-20End: 2024-12-31Target: 135Updated: 2024-10-30

IMM2902 in Patients With Advanced Solid Tumors Expressing HER2

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.Advanced Cholangiocarcinoma, Advanced Gastric Carcinoma, Advanced Lung Cancer +1

Start: 2022-02-15End: 2024-10-31Target: 105Updated: 2023-04-10

Related Papers

Abstract 2938: Preclinical development of a novel bispecific mAb-Trap fusion protein, IMM2902, targeting both HER2 and CD47 as cancer immunotherapy

Cancer Research2023-04-044 citations